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Introduction

Results

Genetic screening and testing has only recently
become an accessible assessment for genetic
risk. Unfortunately, these technologies have
been underutilized in minority populations
despite their usefulness for predicting diseases
like sickle cell disease (SCD), often found in
African American and Black and Hispanic
1
populations. We surveyed prenatal patients to
understand current choices, beliefs and
experiences surrounding genetic screening and
testing, specifically for sickle cell disease.
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Survey Questions

In this cross-sectional survey, we collected
information from 322 women during prenatal
visits from July 2019 through May 2021.
Responses to questions about pregnancy
screening and testing practices were analyzed
for trends to identify barriers to care and
education about testing and screening for sickle
cell disease. Patients were asked to rate
whether they agree or disagree with statements
regarding sickle cell health behaviors. We used
2
χ tests to compare categorical variables by
self-reported race. Binary logistic regression
was used to determine the odds ratios and
confidence intervals for each outcome.

Figure 1: The graph depicts survey responses and odds ratios between White and Black patients. The * depicts statistically
significant results from left to right: (p=0.047, OR 95% CI= 0.455 [0.210-0.989]); (p=0.049, OR 95% CI = 0.299 [0.090-0.993]);
(p=0.011, OR 95% CI=0.207 [0.081-0.526])

Conclusions
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Our findings suggest gaps in screening, testing,
and educational efforts between African
American/Black and White patients, as well as
differences in opinions regarding pregnancy
management with a family history or gestational
diagnosis of sickle cell disease. Future research
should focus on decreasing these healthcare gaps
and improving education that address concerns
about SCD for relevant populations.
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